KRAS and neoplasm: We report here the engineering of the KRAS-specific DARPin K19 (herein referred to as DP KRAS)3 into a KRAS-specific degrader and compare the efficacy and tumour-specificity with an engineered pan-RAS degrader, made from the previously described pan-RAS intracellular single domain antibody7,46.